Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

BioAtla (BCAB) Return on Sales (2020 - 2025)

BioAtla's Return on Sales history spans 5 years, with the latest figure at 4.59% for Q4 2025.

  • For Q4 2025, Return on Sales rose 182.0% year-over-year to 4.59%; the TTM value through Dec 2025 reached 29.23%, down 2282.0%, while the annual FY2025 figure was 29.23%, 2282.0% down from the prior year.
  • Return on Sales reached 4.59% in Q4 2025 per BCAB's latest filing, up from 5.63% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.96% in Q3 2024 to a low of 406.61% in Q1 2022.
  • Average Return on Sales over 4 years is 144.14%, with a median of 63.97% recorded in 2021.
  • Peak YoY movement for Return on Sales: plummeted -31103bps in 2021, then soared 182bps in 2025.
  • A 4-year view of Return on Sales shows it stood at 384.37% in 2021, then decreased by -6bps to 406.61% in 2022, then skyrocketed by 98bps to 6.42% in 2024, then grew by 28bps to 4.59% in 2025.
  • Per Business Quant, the three most recent readings for BCAB's Return on Sales are 4.59% (Q4 2025), 5.63% (Q2 2025), and 5.87% (Q1 2025).